---
title: "Descartes-08 in Generalized myasthenia gravis: AURORA"
description: "Formulary evidence on Descartes-08 in Generalized myasthenia gravis: AURORA. Covers Objective, Location and study date, Study design, Eligibility criteria, Treatment, Study outcomes, and 2 further headings. 34 evidence topics quoted from 10 sources."
canonical: "https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/clinical-evidence/aurora"
published: "2026-11-19T12:09:07-05:00"
modified: "2026-11-19T12:09:07-05:00"
---

# Descartes-08 in Generalized myasthenia gravis: AURORA

<a id="heading-3.1.1"></a>

## 3.1.1 AURORA

<a id="heading-3.1.1.1"></a>

### 3.1.1.1 Objective

<a id="topic-3.1.1.1-1"></a>

#### Primary objective: proportion of MG-ADL responders at Month 4

> “To evaluate the efficacy of Descartes-08 as assessed by the proportion of Myasthenia Gravis Activities of Daily Living (MG-ADL) responders at Month 4.”

Source: [ClinicalTrials.gov NCT06799247](https://clinicaltrials.gov/study/NCT06799247)

<a id="topic-3.1.1.1-2"></a>

#### Study purpose and population: adults with AChR antibody-positive generalized myasthenia gravis

> “The AURORA Study is evaluating the safety, tolerability, and efficacy of an investigational mRNA CAR T-cell therapy known as Descartes-08 in adults with acetylcholine receptor autoantibody -positive generalized myasthenia gravis.”

Source: [ClinicalTrials.gov NCT06799247](https://clinicaltrials.gov/study/NCT06799247)

<a id="heading-3.1.1.2"></a>

### 3.1.1.2 Location and Study Date

<a id="topic-3.1.1.2-1"></a>

#### Registry study dates and recruitment status, September 2026 record

> “Study Start (Actual) 2025-05-06”
> “Primary Completion (Estimated) 2026-12-30”
> “Study Completion (Estimated) 2027-09-30”
> “Active, not recruiting No longer looking for participants”
> “Last Update Posted 2026-09-01”

Source: [ClinicalTrials.gov NCT06799247](https://clinicaltrials.gov/study/NCT06799247)

<a id="topic-3.1.1.2-2"></a>

#### Trial initiation: company statement

> “In May 2025, we initiated our Phase 3 AURORA trial of Descartes-08 in patients with MG.”

Source: [Cartesian Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1453687/000145368726000064/rnac-20251231.htm)

<a id="topic-3.1.1.2-3"></a>

#### Registry site count and site locations by country

> “This study has 34 locations”

Source: [ClinicalTrials.gov NCT06799247](https://clinicaltrials.gov/study/NCT06799247)

| Country | Site locations listed in the registry |
| --- | --- |
| United States | “Tucson, Arizona, United States, 85718”; “Carlsbad, California, United States, 92011”; “Los Angeles, California, United States, 90095”; “Orange, California, United States, 92868”; “Aurora, Colorado, United States, 80045”; “Washington D.C., District of Columbia, United States, 20007”; “Maitland, Florida, United States, 32751”; “Tampa, Florida, United States, 33612”; “O'Fallon, Illinois, United States, 62269”; “Fairway, Kansas, United States, 66205”; “Lexington, Kentucky, United States, 40536”; “Boston, Massachusetts, United States, 02111”; “Amherst, New York, United States, 14226”; “New York, New York, United States, 10027”; “New York, New York, United States, 10065”; “Chapel Hill, North Carolina, United States, 27599”; “Charlotte, North Carolina, United States, 28204”; “Portland, Oregon, United States, 97239”; “Philadelphia, Pennsylvania, United States, 19104”; “Pittsburgh, Pennsylvania, United States, 15213”; “Houston, Texas, United States, 77030”; “Seattle, Washington, United States, 98195”; “Milwaukee, Wisconsin, United States, 53215” |
| Canada | “Toronto, Canada” |
| Italy | “Rome, Italy” |
| Poland | “Krakow, Poland” |
| Serbia | “Belgrade, Serbia” |
| Spain | “Barcelona, Spain”; “Madrid, Spain” |
| Turkey | “Ankara, Turkey (Türkiye)”; “Istanbul, Turkey (Türkiye)” |
| United Kingdom | “Birmingham, United Kingdom”; “Sheffield, United Kingdom” |

Source: [ClinicalTrials.gov NCT06799247](https://clinicaltrials.gov/study/NCT06799247)

<a id="topic-3.1.1.2-4"></a>

#### European Union member states, start of trial, and recruitment end dates

> “Locations Italy, Poland, Spain”
> “Start of trial 10/10/2025”
> “Spain Ongoing, recruitment ended 01/08/2025 08/05/2026 10/10/2025 25/11/2025 31/07/2026”
> “Poland Ongoing, recruitment ended 04/08/2025 08/05/2026 09/12/2025 21/01/2026 31/07/2026”
> “Italy Ongoing, recruitment ended 06/08/2025 07/05/2026 27/01/2026 04/03/2026 31/07/2026”
> “Estimated global end date of the trial: 30/09/2027”

Source: [EU Clinical Trials Information System 2024-520355-25-00](https://euclinicaltrials.eu/ctis-public/view/2024-520355-25-00)

<a id="topic-3.1.1.2-5"></a>

#### Estimated primary completion, March 2026 record, superseded in August 2026

> “Primary Completion 2026-11-30 [Estimated]”

Source: [ClinicalTrials.gov NCT06799247 record version 16](https://clinicaltrials.gov/study/NCT06799247?tab=history&a=16)

<a id="heading-3.1.1.3"></a>

### 3.1.1.3 Study Design

<a id="topic-3.1.1.3-1"></a>

#### Randomized, double-blind, placebo-controlled, multicenter phase 3 design

> “This is a randomized, double-blind, placebo-controlled, multi-center phase 3 trial to evaluate the efficacy, safety and tolerability of autologous T-cells expressing a chimeric antigen receptor (CAR) directed to B-Cell maturation antigen (BCMA) in patients with antibody positive gMG.”
> “Allocation : Randomized”
> “Interventional Model : Crossover Assignment”

Source: [ClinicalTrials.gov NCT06799247](https://clinicaltrials.gov/study/NCT06799247)

<a id="topic-3.1.1.3-2"></a>

#### One-to-one randomization to six once-weekly outpatient infusions without preconditioning chemotherapy

> “The randomized, double-blind, placebo-controlled Phase 3 AURORA trial is designed to assess Descartes-08, Cartesian’s autologous anti-B cell maturation antigen (BCMA) chimeric antigen receptor T-cell therapy (CAR-T) versus placebo (1:1 randomization) administered as six once-weekly outpatient infusions without preconditioning chemotherapy in approximately 100 patients with acetylcholine receptor autoantibody positive (AChR Ab+) MG.”

Source: [Cartesian Therapeutics third quarter 2026 results (2026)](https://ir.cartesiantherapeutics.com/news-releases/news-release-details/cartesian-therapeutics-reports-third-quarter-2026-financial)

<a id="topic-3.1.1.3-3"></a>

#### Two study parts: double-blind Part 1 and open-label Part 2

> “Part 1 of the study will last around 6 months. For eligible participants, Part 2 will last around 8 months.”
> “Masking Description: first part of the study is double blinided and the second part of the study is open label”

Source: [ClinicalTrials.gov NCT06799247](https://clinicaltrials.gov/study/NCT06799247)

<a id="topic-3.1.1.3-4"></a>

#### Masked dosing and follow-up to Month 4, then optional Descartes-08 infusions: company trial schema

> “AURORA: Randomized double-blind, placebo-controlled Phase 3 trial of Descartes-08 in AChR Ab+ gMG with data expected in 1Q27”
> “Optional Descartes-08 infusions Follow-Up Month 5, Month 6, Month 9, Month 12”

Source: [Cartesian Therapeutics corporate presentation, May 2026 (2026)](https://www.sec.gov/Archives/edgar/data/1453687/000145368726000087/rnaccorpdeckmay2026.htm)

<a id="topic-3.1.1.3-5"></a>

#### FDA Special Protocol Assessment agreement on the trial design, January 2025

> “In January 2025, we received written agreement from the FDA under the Special Protocol Assessment, or SPA, process on the overall design of our planned AURORA trial.”
> “The SPA agreement indicates that the FDA has determined that the proposed trial design is acceptable to support a future Biologics License Application, or BLA, for Descartes-08 in MG, subject to the ultimate outcome of the trial.”

Source: [Cartesian Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1453687/000145368726000064/rnac-20251231.htm)

<a id="heading-3.1.1.4"></a>

### 3.1.1.4 Eligibility Criteria

<a id="topic-3.1.1.4-1"></a>

#### Age, disease classification, and MG-ADL threshold

> “Patient must be at least 18 years of age.”
> “Patient must have generalized myasthenia gravis (gMG), Myasthenia Gravis Foundation of America (MGFA) clinical classification grades 2-4 at the time of Sscreening.”
> “MG-Activities of Daily Living (MG ADL) total score ≥ 6.”

Source: [ClinicalTrials.gov NCT06799247](https://clinicaltrials.gov/study/NCT06799247)

<a id="topic-3.1.1.4-2"></a>

#### Acetylcholine receptor antibody requirement

> “Acetylcholine receptor autoantibody (anti-nAChR) titer or anti-AChR cluster antibody must be above the reference laboratory upper normal limit (UNL) and documented within the past 10 years of screening.”

Source: [ClinicalTrials.gov NCT06799247](https://clinicaltrials.gov/study/NCT06799247)

<a id="topic-3.1.1.4-3"></a>

#### Background immunosuppressive therapy and corticosteroid dose

> “Concomitant immunosuppressive drugs must be deemed necessary by the investigator. The dose must be stable for a minimum of 8 weeks prior to Baseline visit.”
> “If a patient is using corticosteroids, the daily dose should not exceed 40 mg/day of prednisone equivalent. The dose must have been stable for a minimum of 8 weeks prior to Baseline visit.”

Source: [ClinicalTrials.gov NCT06799247](https://clinicaltrials.gov/study/NCT06799247)

<a id="topic-3.1.1.4-4"></a>

#### Exclusions for disease duration, treatment history, and other neuromuscular disease

> “Diagnosis of gMG within 12 months of screening.”
> “No history of systemic treatment for gMG other than acetylcholine esterase inhibitors.”
> “Diagnosis of a neuromuscular disease other than gMG.”
> “Patient is pregnant or lactating.”

Source: [ClinicalTrials.gov NCT06799247](https://clinicaltrials.gov/study/NCT06799247)

<a id="topic-3.1.1.4-5"></a>

#### Washout periods for IVIg, plasma exchange, B-cell depleting agents, FcRn antagonists, and complement inhibitors

> “Treatment with intravenous immunoglobulin (IVIG) or plasma exchange within 4 weeks prior to the Baseline visit.”
> “Treatment with rituximab or ocrelizumab within 12 months prior to Baseline visit; treatment with calcineurin inhibitors (e.g. tacrolimus, cyclosporine, cyclophosphamide), Neonatal Fc receptor antagonists, and/or other biologics within 3 weeks prior to planned leukapheresis and within 8 weeks prior to Baseline visit.”
> “The patient has started treatment with a complement 5a (C5a) inhibitor, such as eculizumab, within 8 weeks of Baseline visit. (NOTE: patients who have been receiving a C5a inhibitor for more than 8 weeks and meet other criteria for enrollment are eligible for treatment).”
> “Prior treatment with B-cell maturation antigen (BCMA)-directed therapy (e.g. monoclonal antibody, T-cell engager, or chimeric antigen receptor T-cell [CAR-T]).”

Source: [ClinicalTrials.gov NCT06799247](https://clinicaltrials.gov/study/NCT06799247)

<a id="topic-3.1.1.4-6"></a>

#### Laboratory exclusions

> “Absolute neutrophil count (ANC) < 1000 cells/microliter.”
> “Hemoglobin < 8.0 g/dL.”
> “Platelets < 50,000/mm3.”
> “Alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) > 3x above normal.”
> “Creatine clearance less than 30 mL/min.”

Source: [ClinicalTrials.gov NCT06799247](https://clinicaltrials.gov/study/NCT06799247)

<a id="topic-3.1.1.4-7"></a>

#### Infection, immunodeficiency, malignancy, and vaccination exclusions

> “History of primary immunodeficiency, organ, or allogeneic bone marrow transplant.”
> “Patients must be seronegative for hepatitis B surface antigen.”
> “History of positive human immunodeficiency virus (HIV) or positive HIV at screening.”
> “Active tuberculosis or positive QuantiFERON test at screening.”
> “History of malignancy that required treatment in the past 3 years, except for squamous cell carcinoma, basal cell carcinoma of the skin, or breast or early-stage colon cancer that is surgically removed and did not require adjuvant chemotherapy or radiotherapy.”
> “Receipt of a live vaccination within 4 weeks prior to Baseline visit or intent to receive live vaccination during the study (Note: messenger RNA [mRNA]-based vaccines such as those against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are not considered live; likewise, the Janssen Covid-19 vaccine is not live).”

Source: [ClinicalTrials.gov NCT06799247](https://clinicaltrials.gov/study/NCT06799247)

<a id="heading-3.1.1.5"></a>

### 3.1.1.5 Treatment

<a id="topic-3.1.1.5-1"></a>

#### Descartes-08 arm: leukapheresis and manufactured autologous mRNA CAR T-cell therapy

> “This group will undergo leukapheresis and receive manufactured Decartes-08”
> “Autologous mRNA CAR T-cell therapy”

Source: [ClinicalTrials.gov NCT06799247](https://clinicaltrials.gov/study/NCT06799247)

<a id="topic-3.1.1.5-2"></a>

#### Placebo arm: infusion without Descartes-08

> “This group will receive placebo”
> “infusion without Decartes-08”

Source: [ClinicalTrials.gov NCT06799247](https://clinicaltrials.gov/study/NCT06799247)

<a id="topic-3.1.1.5-3"></a>

#### Six weekly masked doses of Descartes-08 or placebo: company trial schema

> “WK1 Masked Dosing Six weekly doses of Descartes-08 or placebo”

Source: [Cartesian Therapeutics corporate presentation, May 2026 (2026)](https://www.sec.gov/Archives/edgar/data/1453687/000145368726000087/rnaccorpdeckmay2026.htm)

<a id="heading-3.1.1.6"></a>

### 3.1.1.6 Study Outcomes

<a id="heading-3.1.1.6.1"></a>

#### 3.1.1.6.1 Rationale for Using MG-ADL Response as the Primary Endpoint

<a id="topic-3.1.1.6.1-1"></a>

##### Primary endpoint: MG-ADL improvement of 3 points or more at Month 4 compared with placebo

> “The primary endpoint will assess the proportion of Descartes-08 participants with an improvement in MG Activities of Daily Living (MG-ADL) score of three points or more at Month 4 compared to placebo.”

Source: [Cartesian Therapeutics third quarter 2026 results (2026)](https://ir.cartesiantherapeutics.com/news-releases/news-release-details/cartesian-therapeutics-reports-third-quarter-2026-financial)

> “Proportion of participants with MG-ADL improvement of ≥3 points at Month 4, relative to placebo”

Source: [Cartesian Therapeutics corporate presentation, May 2026 (2026)](https://www.sec.gov/Archives/edgar/data/1453687/000145368726000087/rnaccorpdeckmay2026.htm)

<a id="topic-3.1.1.6.1-2"></a>

##### Secondary endpoints: safety, MGC improvement of 4 points or more, QMG, and MG-QoL-15r

> “Secondary endpoints will assess safety and tolerability and the proportion of participants with a reduction of four points or more in MG Composite, or MGC, score, as well as improvements in other validated MG severity scales, including QMG, and MG Quality of Life Revised Scale, or MG-QoL-15R.”

Source: [Cartesian Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1453687/000145368726000064/rnac-20251231.htm)

<a id="topic-3.1.1.6.1-3"></a>

##### Secondary endpoints at Month 4 and over 1 year: company trial schema

> “Proportion of participants with MGC improvement of ≥4 points at Month 4”
> “MG-ADL and MGC change from baseline to Month 4”
> “Quantify clinical effect of Descartes-08 over 1 year”

Source: [Cartesian Therapeutics corporate presentation, May 2026 (2026)](https://www.sec.gov/Archives/edgar/data/1453687/000145368726000087/rnaccorpdeckmay2026.htm)

<a id="topic-3.1.1.6.1-4"></a>

##### MG-ADL instrument and its use as a primary endpoint in trials

> “The Myasthenia Gravis Activities of Living (MG‐ADL) scale is an 8‐item patient‐reported scale that measures myasthenia gravis (MG) symptoms and functional status.”
> “Of trials beginning in 2018 or later, 46.7% (n = 7) have used the MG‐ADL as a primary outcome compared to 10.0% (n = 2) of trials prior to 2018 (Figure 1).”

Source: [Muppidi et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9302997/)

<a id="topic-3.1.1.6.1-5"></a>

##### Sensitivity and specificity of 1-point and 3-point MG-ADL changes, and responder thresholds used in trials

> “In this study, results from sensitivity and specificity analyses indicated that a 1‐point change in MG‐ADL was highly sensitive (96%) but did not have good specificity (71%), and a 3‐point change had good specificity (90%) but was not very sensitive (62%).”
> “Of these 13 studies, 53.8% (n = 7) used a 2‐point improvement only, 30.8% (n = 4) used a 3‐point improvement only, 7.6% (n = 1) showed results for improvements ranging from 2 to 8 points, and 7.6% (n = 1) did not report how an MG‐ADL responder was defined.”
> “A 2‐point responder threshold has been established in the mild to moderate MG population, but further research is needed to determine the appropriate responder threshold for a severe MG population.”

Source: [Muppidi et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9302997/)

<a id="topic-3.1.1.6.1-6"></a>

##### Precedent for a 3-point MG-ADL responder definition: REGAIN and the eculizumab label

> “Results from the REGAIN trial showed that increasing the stringency of the responder definition at week 26 with higher thresholds revealed a more substantial difference between eculizumab and placebo (3‐point MG‐ADL improvement: 60% eculizumab responders, 40% placebo responders, P = .0229; 5‐point MG‐ADL improvement: 45% eculizumab responders, 25% placebo responders, P = .0182; 7‐point MG‐ADL improvement: 34% eculizumab responders, 10% placebo responders, P = .0007).”
> “Currently, there is no publicly available regulatory guidance from the FDA on an appropriate MG‐ADL responder threshold, although the FDA label for eculizumab refers to REGAIN study results using a 3‐point improvement.”

Source: [Muppidi et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9302997/)

<a id="topic-3.1.1.6.1-7"></a>

##### Expert criticism of the MG-ADL as a phase 3 primary endpoint

> “Although important to measure, the MG-Activities of Daily Living (MG-ADL) was thought not to assess the breadth of relevant daily activities.”
> “As such, the MG-ADL score was considered “not appropriate” as a primary endpoint for phase 3 trials and was considered “a bar too low” for approval of a therapy, especially given the threshold of a 2-point improvement for clinically meaningful improvement.”

Source: [Benatar et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9780175/)

<a id="heading-3.1.1.7"></a>

### 3.1.1.7 Statistical Analysis Description

<a id="heading-3.1.1.7.1"></a>

#### 3.1.1.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.1.7.1-1"></a>

##### Planned enrollment of approximately 100 participants: company statement, March 2026

> “Our top priority remains delivering on our Phase 3 AURORA trial in myasthenia gravis (MG), for which we are on track to enroll approximately 100 patients.”

Source: [Cartesian Therapeutics full year 2025 results (2026)](https://ir.cartesiantherapeutics.com/news-releases/news-release-details/cartesian-therapeutics-reports-full-year-2025-financial-results)

<a id="topic-3.1.1.7.1-2"></a>

##### Actual registry enrollment, September 2026 record

> “Enrollment (Actual) 128”

Source: [ClinicalTrials.gov NCT06799247](https://clinicaltrials.gov/study/NCT06799247)

<a id="topic-3.1.1.7.1-3"></a>

##### Estimated registry enrollment, March 2026 record, superseded in August 2026

> “Enrollment 100 [Estimated]”

Source: [ClinicalTrials.gov NCT06799247 record version 16](https://clinicaltrials.gov/study/NCT06799247?tab=history&a=16)

<a id="heading-3.1.1.7.2"></a>

#### 3.1.1.7.2 Description of Analysis Sets

No evidence found.

<a id="heading-3.1.1.8"></a>

### 3.1.1.8 Results

<a id="heading-3.1.1.8.1"></a>

#### 3.1.1.8.1 Participant Disposition

No evidence found.

<a id="heading-3.1.1.8.2"></a>

#### 3.1.1.8.2 Baseline Characteristics

No evidence found.

<a id="heading-3.1.1.8.3"></a>

#### 3.1.1.8.3 Efficacy Results

No evidence found.

<a id="heading-3.1.1.8.4"></a>

#### 3.1.1.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.1.8.5"></a>

#### 3.1.1.8.5 Safety Results

No evidence found.

<a id="heading-3.1.1.9"></a>

### 3.1.1.9 Study Limitations

<a id="topic-3.1.1.9-1"></a>

#### Summary

- AURORA has reported no efficacy or safety results. The registry record (last update posted 2026-09-01) lists the study as active and not recruiting, with estimated primary completion on 2026-12-30 and estimated study completion on 2027-09-30; record version 16 had listed estimated primary completion on 2026-11-30. The company expects a data readout in the first quarter of 2027.
- Enrollment differs by source: the company states approximately 100 participants, registry record version 16 listed an estimated enrollment of 100, and the current registry record lists an actual enrollment of 128.
- The primary endpoint is the proportion of participants with an MG-ADL improvement of 3 points or more at month 4 compared with placebo. The registry lists a crossover assignment model, a double-blind Part 1 of about 6 months, and an open-label Part 2 of about 8 months for eligible participants, and the company trial schema shows optional Descartes-08 infusions with follow-up at months 5, 6, 9, and 12.
- The phase 2b report stated plans to use the MGC score as the primary outcome in a subsequent phase 3 trial; in AURORA, MGC improvement of 4 points or more at month 4 is a secondary endpoint. One publication reports that the MG-ADL score was considered “a bar too low” for approval of a therapy given the 2-point threshold for clinically meaningful improvement. Another reports that a 3-point MG-ADL change had a specificity of 90% and a sensitivity of 62%, that no publicly available FDA guidance on an MG-ADL responder threshold exists, and that the eculizumab label refers to REGAIN results using a 3-point improvement.
- Eligibility is limited to adults with an anti-AChR antibody titer or anti-AChR cluster antibody above the reference upper normal limit, MGFA class 2 to 4, and an MG-ADL total score of 6 or more. Participants diagnosed within 12 months of screening, those with no history of systemic gMG treatment other than acetylcholinesterase inhibitors, those treated with rituximab or ocrelizumab within 12 months, and those with prior BCMA-directed therapy are excluded. In the phase 2b mITT population, 6 participants (23.1%) were triple seronegative and 1 (3.8%) was LRP4 autoantibody-positive.
- The company's Form 10-K states that a trial conducted under a Special Protocol Assessment agreement that meets its endpoints carries no guarantee that the FDA will accept or approve a marketing application.

Source: [ClinicalTrials.gov NCT06799247](https://clinicaltrials.gov/study/NCT06799247); [ClinicalTrials.gov NCT06799247 record version 16](https://clinicaltrials.gov/study/NCT06799247?tab=history&a=16); [Cartesian Therapeutics full year 2025 results (2026)](https://ir.cartesiantherapeutics.com/news-releases/news-release-details/cartesian-therapeutics-reports-full-year-2025-financial-results); [Cartesian Therapeutics third quarter 2026 results (2026)](https://ir.cartesiantherapeutics.com/news-releases/news-release-details/cartesian-therapeutics-reports-third-quarter-2026-financial); [Cartesian Therapeutics corporate presentation, May 2026 (2026)](https://www.sec.gov/Archives/edgar/data/1453687/000145368726000087/rnaccorpdeckmay2026.htm); [Cartesian Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1453687/000145368726000064/rnac-20251231.htm); [Vu et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13004676/); [Benatar et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9780175/); [Muppidi et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9302997/)

<a id="topic-3.1.1.9-2"></a>

#### Special Protocol Assessment agreement does not guarantee approval

> “Even if the sponsor conducts the trial in accordance with an SPA agreement and the trial meets its endpoints with statistical significance, there is no guarantee that the FDA will accept or approve a marketing application.”

Source: [Cartesian Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1453687/000145368726000064/rnac-20251231.htm)

## Related pages
- [Descartes-08: Generalized myasthenia gravis](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis.md)
- [Descartes-08 in Generalized myasthenia gravis: Terms and abbreviations](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/terms-and-abbreviations.md)
- [Descartes-08: Generalized myasthenia gravis](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/executive-summary.md)
- [Descartes-08 in Generalized myasthenia gravis: Product information and disease description](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/product-information-and-disease-description.md)
- [Descartes-08 in Generalized myasthenia gravis: Clinical evidence](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/clinical-evidence.md)
- [Descartes-08 in Generalized myasthenia gravis: Economic information and modeling report](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/economics) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/economics.md)
- [Descartes-08 in Generalized myasthenia gravis: References](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/references) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/references.md)
